Cognition Therapeutics, Inc.
CGTX
$0.3724
-$0.0008-0.21%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -16.35% | -0.97% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -25.86% | -1.46% | |||
| Operating Income | 25.86% | 1.46% | |||
| Income Before Tax | 21.08% | -41.13% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 21.08% | -41.13% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 21.08% | -41.13% | |||
| EBIT | 25.86% | 1.46% | |||
| EBITDA | 25.91% | 1.47% | |||
| EPS Basic | 28.63% | -39.95% | |||
| Normalized Basic EPS | 26.87% | -39.98% | |||
| EPS Diluted | 29.36% | -38.89% | |||
| Normalized Diluted EPS | 26.87% | -39.98% | |||
| Average Basic Shares Outstanding | 10.54% | 0.89% | |||
| Average Diluted Shares Outstanding | 10.54% | 0.89% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||